Mirum Pharmaceuticals reported strong third-quarter results, achieving $133 million in revenue — nearly a 50% year-over-year increase, driven by robust sales of LIVMARLI and a solid pipeline of clinical studies.

• LIVMARLI net product sales reached $92 million, supported by healthy demand across U.S. markets and strong international growth.
• Company achieved positive net income for the first time, highlighting effective operational leverage in its business model.
• Enrollment in the pivotal Phase IIb VISTAS study for volixibat in primary sclerosing cholangitis is complete, with top-line data expected in Q2 2026.
• Full-year revenue guidance has been raised to $500 million-$510 million, reflecting sustained strong performance across product lines.
• Continued growth potential anticipated for key products, with peak revenue opportunities exceeding $1 billion for LIVMARLI, volixibat, and MRM-3379.